Clinical trial
Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the…
NCT00210743 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00210743 |
|---|---|
| Title | Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia. |
| Official title | An Open-Label, Clinical Evaluation of the Initiation of Every 2 Week Epoetin Alfa (PROCRIT)in the Treatment of Subjects With the Anemia of Chronic Kidney Disease (CKD) |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Ortho Biotech Products, L.P. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Kidney Diseases |
| Intervention type | Drug |
| Interventions | epoetin alfa |
| Enrollment | 67 |
| Start date | May 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | May 23, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: